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It is crystal clear that lowering blood pressure (BP) to levels recommended by most guidelines reduces cardiovascular mortality. [1] [2] [3] However, in spite of strong guideline recommendations for initial use of single-pill combination BP meds in most people dating back to 2003, it is rarely initiated as first-line therapy. 4, 5 The most recent North American and European BP guidelines strongly support initial single-pill combination therapy for people with BP 20/10 mmHg above the goal. [1] [2] [3] 6 . Moreover, most clinical trials since 2000 that randomized various monotherapies to evaluate cardiovascular (CV) outcome ultimately required an average of two or more medications to achieve the BP goal. 7 The evidence of improved CV outcomes with initial single-pill combination therapy in hypertension dates back to the late 1960s when the Veteran Affairs Cooperative study showed reduced CV events in patients received double to triple combination therapy. 8 However, this approach was not supported by early guidelines, and step-care management remained the standard until 1996 when the sixth Joint National Committee report (JNC 6) first supported fixeddose combination therapy. Subsequently, as evidence becomes stronger for their use in 2003, the JNC 7 strongly endorsed initial single-pill combinations for BP lowering, an endorsement which is even stronger in more recent guidelines. 1, 2, 9 In this issue of the European Heart Journal, Rea and colleagues examined a healthcare utilization database from the Lombardy Region of Italy and evaluated morbidity outcomes among 44 534 residents who started treatment with either one antihypertensive drug (n = 37 078) or a two-drug single-pill combination (n = 7456). 10 These patients were followed for 1 year to compare the risk of hospitalization from CV disease. To limit confounding, the authors matched the two groups using a high-dimensional propensity score as well as comparing patients experiencing one or more CV events.
Compared with initial monotherapy, patients on single-pill combination treatment demonstrated a 21% reduction (P < 0.01) in 1-year risk of hospitalization for any CV event. Moreover, in patients experiencing CV events, there was a 56% lower incidence (P < 0.01) among those taking single-pill combinations compared with those on monotherapy. The authors concluded that a single-pill fixed-drug combination strategy in hypertensive patients offers more CV protection compared with monotherapy.
The results of this study continue to add to the already large database and multiple guidelines strongly supporting initial single-pill combination BP-lowering therapy. In addition to achieving BP control faster and with fewer adverse events, there is also a large database supporting improved adherence of BP medications. 11, 12 Single-pill BP-lowering therapy improves medication adherence and has fewer adverse effects when compared with doubling the dose of a single medication to achieve the BP goal. 13, 14 Additionally, initial single-pill combination treatment avoids therapeutic inertia, or physician inaction in the face of a BP that is above target. 7, 14 This inaction by physicians is known to have a significant effect on the degree of BP control and accounts for almost 20% of the variance in control. It is also projected that if medication changes were made in 30% of visits, the proportion of patients reaching BP target would rise from 40.1% to 65.9%.
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Medication adherence is a major public health concern as it is a major contributor to not achieving BP targets. In two separate studies where adherence to BP medications was documented by assessing urine metabolites, only 45% of patients were taking their prescribed medications. 15, 16 Many studies have shown that single-pill combinations markedly improve these percentages.
4,12
The authors' findings of reduced CV morbidity are also supported by the randomized outcome trial ACCOMPLISH as well as the systematic review by Gradman and colleagues 17, 18 who evaluated the impact of single-pill combination therapy on the CV outcomes in an observational, matched controlled study similar to that of Rea et al.
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However, unlike Rea and colleagues, Gradman et al. included singlepill and free drug combinations compared with single medications, and defined BP values as >140/90 mmHg or >130/80 mmHg among those with diabetes or chronic kidney disease. More patients achieved BP target in the combination group after 6 months with a significant reduction in CV events (54% vs. 46%, P = 0.0008). 18 Rea and colleagues should appreciate, however, that variables other than medications could have contributed to their results. Such variables include sodium intake, weight loss, and sleep quality, which were not assessed. Additionally, the authors do not mention the BP level when treatment was initiated. Thus, it is unclear what the magnitude of BP lowering was in each group.
Taken together, this study reaffirms the need to use initial singlepill combinations for BP lowering. All single-pill combinations available and approved by regulatory agencies have demonstrated additive BP-lowering efficacy with fewer adverse events compared with individual higher dosed components. 7 A detailed discussion of initial single-pill combinations and their efficacy for reduction of BP and CV events is presented in the American Society of Hypertension Consensus Report.
